The presentations will include updated clinical data from the phase 1A/B study of AB248, Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, alone and in combination ...
Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response ...
Human-induced pluripotent stem cell-derived cardiomyocyte sheets can be a life-saving intervention for patients with advanced cardiovascular disease. Administration of immunosuppressive agents to ...
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in ...
Jody Baron and Gabi Fragiadakis discover why some people with chronic Hepatitis B are cured after they're taken off of ...
Morning Overview on MSN
Two new pancreatic cancer treatments — a targeted pill and a personalized mRNA vaccine — are beating back one of medicine’s deadliest tumors in early trials
Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after ...
Detailed price information for Biovaxys Technology Corp (BVAXF) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results